loading page

Pediatric Patients with Von Hippel-Lindau and Hemangioblastomas Treated Successfully with Belzutifan
  • +7
  • Emily Duan,
  • Michael Robinson,
  • Charles Davis,
  • Sumit Pruthi,
  • Marisa Lewis,
  • Julian Martinez-Agosto,
  • Michael B. Gorin,
  • Brian M. Shuch,
  • Debra Friedman,
  • Vivian Chang
Emily Duan
University of California Los Angeles Department of Pediatrics
Author Profile
Michael Robinson
Vanderbilt University Medical Center Vanderbilt O'Brien Kidney Center
Author Profile
Charles Davis
Ronald Reagan UCLA Medical Center
Author Profile
Sumit Pruthi
Vanderbilt University Medical Center Vanderbilt O'Brien Kidney Center
Author Profile
Marisa Lewis
University of California Los Angeles Department of Pediatrics
Author Profile
Julian Martinez-Agosto
University of California Los Angeles Department of Human Genetics
Author Profile
Michael B. Gorin
UCLA Jules Stein Eye Institute
Author Profile
Brian M. Shuch
University of California Los Angeles Jonsson Comprehensive Cancer Center
Author Profile
Debra Friedman
Vanderbilt University Medical Center Vanderbilt O'Brien Kidney Center
Author Profile
Vivian Chang
University of California Los Angeles Department of Pediatrics

Corresponding Author:vchang@mednet.ucla.edu

Author Profile

Abstract

Hemangioblastomas are the most common tumor associated with Von Hippel-Lindau (VHL) and a leading cause of mortality. We present five pediatric patients with VHL-associated hemangioblastomas treated with belzutifan, a HIF2a inhibitor. Three patients were started on belzutifan due to vision loss from progressive retinal hemangioblastomas. Within 1 year of treatment, all three patients had improvement in hemangioblastoma size and visual acuity. For patients with intracranial lesions, belzutifan resulted in an improvement in neurologic symptoms and hemangioblastoma size. Four patients experienced grade 1-2 anemia and two patients required a dose reduction. Our report suggests that belzutifan can be an effective therapy for pediatric patients with VHL-associated hemangioblastomas.
29 Apr 2024Submission Checks Completed
29 Apr 2024Assigned to Editor
29 Apr 2024Submitted to Pediatric Blood & Cancer
08 May 2024Reviewer(s) Assigned
26 May 2024Review(s) Completed, Editorial Evaluation Pending
27 May 2024Editorial Decision: Revise Major
24 Aug 20241st Revision Received
24 Aug 2024Submission Checks Completed
24 Aug 2024Assigned to Editor
28 Aug 2024Review(s) Completed, Editorial Evaluation Pending
01 Sep 2024Reviewer(s) Assigned
23 Sep 2024Editorial Decision: Accept